In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

Published Date: 03 Jun 2024

surprisingly provides a potential boost to overall survival, according to researchers.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

2.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

3.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

4.

Month-Long Wait Times Caused by US Physician Shortage.

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot